EP Patent

EP3290023B1 — Rivastigmine-containing sustained-release pharmaceutical composition

Assigned to Navipharm Co Ltd · Expires 2021-02-17 · 5y expired

What this patent protects

Patent listed against bupropion-hydrochloride.

Drugs covered by this patent

bupropion-hydrochloride (BUPROPION HYDROCHLORIDE)

Patent Metadata

Patent number: EP3290023B1
Jurisdiction: EP
Classification: —
Expires: 2021-02-17
Drug substance claim: No
Drug product claim: No
Assignee: Navipharm Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.